Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Trial Shift And Renewed Analyst Optimism [Yahoo! Finance]
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: Yahoo! Finance
The FDA's decision to relax certain safety screening and testing requirements for claseprubart trials, alongside William Blair's reaffirmed positive view, has put Dianthus Therapeutics (DNTH) squarely in focus for biotech investors. See our latest analysis for Dianthus Therapeutics. Despite a 2.7% one day share price decline and a 4.9% 7 day share price pullback to US$87.39, Dianthus still shows a 7.7% 1 month share price return, a 73.7% 3 month share price return and a very large 1 year total shareholder return of about 3x. This suggests that recent regulatory progress and trial plans remain key drivers of sentiment. If this kind of biotech momentum has your attention, it may be worth scanning for other healthcare names using our screener for 33 healthcare AI stocks With Dianthus now valued at about US$4.8b and trading at US$87.39, some investors may see the near-term pullback and the discount to analyst targets as attractive. However, this raises the question of whether thi
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics (DNTH) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Dianthus Therapeutics (DNTH) was upgraded by Wolfe Research to "strong-buy".MarketBeat
- Dianthus Therapeutics (DNTH) is now covered by Wolfe Research. They set an "outperform" rating and a $98.00 price target on the stock.MarketBeat
DNTH
Earnings
- 3/9/26 - Miss
DNTH
Sec Filings
- 4/27/26 - Form SCHEDULE
- 4/10/26 - Form 4
- 4/9/26 - Form 144
- DNTH's page on the SEC website